medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-34-36-41medalphabet-4144Research ArticleСтатьиПостинфекционный синдром раздраженного кишечника: акцент на нарушения метаболизма серотонина и модуляцию кишечной микробиотыPost-infectious irritable bowel syndrome: Focus on serotonin metabolism disturbances and gut microbiota modulationhttps://orcid.org/0000-0001-9370-4768ГаусО. В.GausO. V.

Гаус Ольга Владимировна, д.м.н., профессор кафедры факультетской терапии и гастроэнтерологии

Омск

Gaus Olga V., DM Sci (habil.), professor at Dept of Faculty Therapy and Gastroenterology

Omsk

gaus_olga@bk.ruФедоренкоА. С.FedorenkoA. S.

Федоренко Алексей Cергеевич, врач общей практики (семейная медицина

Омск

Sudakova Alla N., PhD Med, associate professor at Dept of Faculty Therapy and Gastroenterology

Omsk

СудаковаA. Н.SudakovaA. N.

Судакова Алла Николаевна, к.м.н., доцент кафедры факультетской терапии и гастроэнтерологии

Омск

Sudakova Alla N., PhD Med, associate professor at Dept of Faculty Therapy and Gastroenterology

Omsk

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian FederationБУЗ Омской области «Клиническая медико-санитарная часть № 7»РоссияClinical Medical and Sanitary Unit No. 7Russian Federation202424012025034Практическая гастроэнтерология (3)3641Copyright © Гаус О.В., Федоренко А.С., Судакова A.Н., 20252025Гаус О.В., Федоренко А.С., Судакова A.Н.Gaus O.V., Fedorenko A.S., Sudakova A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4144

Постинфекционный синдром раздраженного кишечника (ПИ-СРК) является первым описанным в литературе и наиболее изученным к настоящему времени фенотипом заболевания, распространенность которого в популяции продолжает неуклонно расти, особенно в период после пандемии COVID-19. С учетом накопленных научных и клинических данных, в качестве ключевого патогенетического фактора, лежащего в основе развития и персистенции симптомов ПИ-СРК, рассматривается дисфункция функциональной оси «микробиота-кишечник-мозг», ассоциированная с формированием висцеральной гиперчувствительности и моторных нарушений кишечника вследствие аномального метаболизма серотонина, повышенной кишечной проницаемости и воспаления низкой степени активности. В данной обзорной статье проанализированы и обобщены сведения о механизмах ПИ-СРК, связанных с изменениями нейрогуморальной регуляции, а также качественного и количественного состава кишечной микробиоты. Кроме того, представлены данные о возможности применения пробиотической терапии в комплексной терапии пациентов с ПИ-СРК.

Post-infectious irritable bowel syndrome (PI–IBS) is the first phenotype of the disease described in the literature and the most studied to date. The prevalence of PI–IBS in the population continues to grow steadily especially in the post-COVID-19 pandemic period. Taking into account the accumulated scientific and clinical data dysfunction of the functional axis «microbiota-gut-brain» associated with the formation of visceral hypersensitivity and intestinal motor disorders due to abnormal serotonin metabolism, increased intestinal permeability and low-grade inflammation is considered as a key pathogenetic factor underlying the development and persistence of PI–IBS symptoms. This review article analyzes and summarizes information on the mechanisms of PI–IBS associated with changes in neurohumoral regulation, as well as the qualitative and quantitative composition of the intestinal microbiota. In addition, data on the possibility of using probiotic therapy in the complex therapy of patients with PI–IBS are presented.

функциональные гастроинтестинальные расстройствапостинфекционный синдром раздраженного кишечникаострая кишечная инфекциякишечная микробиотапробиотикивисцеральная гиперчувствительностьсеротонинfunctional gastrointestinal disorderspost-infectious irritable bowel syndromeacute intestinal infectionintestinal microbiotaprobioticsvisceral hypersensitivityserotoninReferencesSperber A. D., Bangdiwala S. I., Drossman D. A., Ghoshal U. C., Simren M., Tack J. et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160:99–114. e3. DOI: 10.1053/j.gastro.2020.04.014Sperber A. D., Bangdiwala S. I., Drossman D. A., Ghoshal U. C., Simren M., Tack J. et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160:99–114. e3. DOI: 10.1053/j.gastro.2020.04.014Ionescu V. A., Gheorghe G., Georgescu T. F., Bacalbasa N., Gheorghe F., Diaconu C. C. The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome. Journal of Clinical Medicine. 2024; 13(17):5124. DOI:10.3390/jcm13175124Ionescu V. A., Gheorghe G., Georgescu T. F., Bacalbasa N., Gheorghe F., Diaconu C. C. The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome. Journal of Clinical Medicine. 2024; 13(17):5124. DOI:10.3390/jcm13175124Black C. J., Drossman D. A., Talley N. J., Ruddy J., Ford A. C. Functional gastrointestinal disorders: Advances in understanding and management. Lancet. 2020; 396: 1664–1674. doi: 10.1016/S0140-6736(20 32115-2Black C. J., Drossman D. A., Talley N. J., Ruddy J., Ford A. C. Functional gastrointestinal disorders: Advances in understanding and management. Lancet. 2020; 396: 1664–1674. doi: 10.1016/S0140-6736(20 32115-2Белова А. А., Шестакова М. Д., Хавкин А. И. Лямблиоз и постинфекционный СРК. Экспериментальная и клиническая гастроэнтерология. 2021;(4):178–187. DOI: 10.31146/1682-8658-ecg-188-4-178-187Belova A. A., Shestakova M. D., Khavkin A. I. Giardiasis and post-infectious IBS. Experimental and Clinical Gastroenterology. 2021;(4):178–187. (In Russ.). DOI: 10.31146/1682-8658-ecg-188-4-178-187Гаус О. В., Ливзан М. А. Фенотипы синдрома раздраженного кишечника: ведущие факторы генетики и эпигенетики, механизмы формирования. Терапевтический архив. 2023; 95(2): 164–172. DOI: 10.26442/00403660.2023.02.202111Gaus O. V., Livzan M. A. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Therapeutic archive. 2023; 95(2): 164–172. (In Russ.). DOI: 10.26442/00403660.2023.02.202111Barbara G. et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. Gastroenterology. 2019; 156(1): 46–58.e7 DOI: 10.1053/j.gastro.2018.07.011Barbara G. et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. Gastroenterology. 2019; 156(1): 46–58.e7 DOI: 10.1053/j.gastro.2018.07.011Marshall J. K., Thabane M., Garg A. X. et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131(2): 445–450. DOI:10.1053/j.gastro.2006.05.053Marshall J. K., Thabane M., Garg A. X. et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131(2): 445–450. DOI:10.1053/j.gastro.2006.05.053Klem F., Wadhwa A., Prokop L. J., Sundt W. J., Farrugia G., Camilleri M., et al. Prevalence, risk factors and outcomes of irritable bowel syndrome after infectious enteritis: a systemic review and meta-analysis. Gastroenterology. 2017; 152(5): 1042–54. DOI: 10.1053/j.gastro.2016.12.039Klem F., Wadhwa A., Prokop L. J., Sundt W. J., Farrugia G., Camilleri M., et al. Prevalence, risk factors and outcomes of irritable bowel syndrome after infectious enteritis: a systemic review and meta-analysis. Gastroenterology. 2017; 152(5): 1042–54. DOI: 10.1053/j.gastro.2016.12.039Svendsen T., Bytzer P., Engsbro A. L. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome? Scand. J. Gastroenterol. 2019; 54: 546–562.Svendsen T., Bytzer P., Engsbro A. L. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome? Scand. J. Gastroenterol. 2019; 54: 546–562.Zanini B., Ricci C., Bandera F., Caselani F., Magni A., Laronga A. M. et al. Incidence of postinfectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012; 107: 891–899. DOI:10.1038/ajg.2012.102.Zanini B., Ricci C., Bandera F., Caselani F., Magni A., Laronga A. M. et al. Incidence of postinfectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012; 107: 891–899. DOI:10.1038/ajg.2012.102.Marshall J. K., Thabane M., Borgaonkar M. R., James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin. Gastroenterol. Hepatol. 2007; 5: 457–460. DOI: 10.1155/2008/847367Marshall J. K., Thabane M., Borgaonkar M. R., James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin. Gastroenterol. Hepatol. 2007; 5: 457–460. DOI: 10.1155/2008/847367Wang Z., Peng Y., Chen M., Peng L., Huang Y., Lin W. The Prevalence of Irritable Bowel Syndrome after Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Their Association: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Med. 2023; 12(5): 1865. DOI: 10.3390/jcm12051865.Wang Z., Peng Y., Chen M., Peng L., Huang Y., Lin W. The Prevalence of Irritable Bowel Syndrome after Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Their Association: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Med. 2023; 12(5): 1865. DOI: 10.3390/jcm12051865.Oshima T., Siah K. T.H., Yoshimoto T. et al. Impacts of the COVID-19 pandemic on functional dyspepsia and IBS: a populationbased survey. J. Gastroenterol Hepatol. 2021; 36 (7): 1820–1827. DOI: 10.1111/jgh.15346.Oshima T., Siah K. T.H., Yoshimoto T. et al. Impacts of the COVID-19 pandemic on functional dyspepsia and IBS: a populationbased survey. J. Gastroenterol Hepatol. 2021; 36 (7): 1820–1827. DOI: 10.1111/jgh.15346.Gros M., Gros B., Mesonero J. E., Latorre E. Neurotransmitter dysfunction in irritable bowel syndrome: emerging approaches for management,. J Clin Med. 2021; 10(15): 3429. DOI: 10.3390/jcm10153429.Gros M., Gros B., Mesonero J. E., Latorre E. Neurotransmitter dysfunction in irritable bowel syndrome: emerging approaches for management,. J Clin Med. 2021; 10(15): 3429. DOI: 10.3390/jcm10153429.Sharp T., Barnes N. M. Central 5-HT receptors and their function; present and future, Neuropharmacology. 2020; 177: 108155. DOI:10.1016/j.neuropharm.2020.108155Sharp T., Barnes N. M. Central 5-HT receptors and their function; present and future, Neuropharmacology. 2020; 177: 108155. DOI:10.1016/j.neuropharm.2020.108155Gershon M. D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders, Gastroenterology. 2007; 132: 397–414Gershon M. D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders, Gastroenterology. 2007; 132: 397–414Rus C. P., de Vries B. E.K., de Vries I. E.J. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep. 2023; 13(1): 18599. DOI: 10.1038/s41598-023-45072-9Rus C. P., de Vries B. E.K., de Vries I. E.J. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep. 2023; 13(1): 18599. DOI: 10.1038/s41598-023-45072-9Visos-Varela I., Zapata-Cachafeiro M., Pineiro-Lamas M., Carracedo-Martinez E., Saez M., Herdeiro M. T. et al. Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study, Eur. Neuropsychopharmacol. 2023; 71: 96–108.Visos-Varela I., Zapata-Cachafeiro M., Pineiro-Lamas M., Carracedo-Martinez E., Saez M., Herdeiro M. T. et al. Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study, Eur. Neuropsychopharmacol. 2023; 71: 96–108.Atkinson W., Lockhart S., Whorwell P. J., Keevil B., Houghton L. A. Altered 5hydroxytryptamine signaling in patients with constipationand diarrheapredominant irritable bowel syndrome, Gastroenterology. 2006; 130: 34–43. DOI: 10.1053/j.gastro.2005.09.031Atkinson W., Lockhart S., Whorwell P. J., Keevil B., Houghton L. A. Altered 5hydroxytryptamine signaling in patients with constipationand diarrheapredominant irritable bowel syndrome, Gastroenterology. 2006; 130: 34–43. DOI: 10.1053/j.gastro.2005.09.031Гаус О. В., Ливзан М. А. Пищевые привычки, уровень тревоги и депрессии у больных синдромом раздраженного кишечника: клинико-лабораторные сопоставления. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023; 33(2): 34–44. DOI: 10.22416/1382-4376-2023-33-2-34-44Gaus O. V., Livzan M. A. Eating habits, anxiety and depression levels in patients with irritable bowel syndrome: clinical and laboratory comparisons. Russian Journal of Gastroenterology, Hepatology, Proctology. 2023; 33(2): 34–44. (In Russ.). DOI: 10.22416/1382-4376-2023-33-2-34-44Spiller R. C., Jenkins D., Thornely J. P. et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Camylobacter enteritis and in post-dysentric irritable bowel syndrome. Gut. 2000; 47: 804–811. DOI: 10.1136/gut.47.6.804Spiller R. C., Jenkins D., Thornely J. P. et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Camylobacter enteritis and in post-dysentric irritable bowel syndrome. Gut. 2000; 47: 804–811. DOI: 10.1136/gut.47.6.804Lee H. S., Lim J. H., Park H., Lee S. I. Increased immunoreactive cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection-an observation in a small case control study. Yonsei Med J. 2009; 51: 45–51. DOI: 10.3349/ymj.2010.51.1.45Lee H. S., Lim J. H., Park H., Lee S. I. Increased immunoreactive cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection-an observation in a small case control study. Yonsei Med J. 2009; 51: 45–51. DOI: 10.3349/ymj.2010.51.1.45Khan W. I., Ghia J. E. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010; 161: 19–27 DOI: 10.1111/j.1365-2249.2010.04150.xKhan W. I., Ghia J. E. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010; 161: 19–27 DOI: 10.1111/j.1365-2249.2010.04150.xEl-Salhy M., Wendelbo I., Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease, Mol. Med. Rep. 2013; 8: 451–455.El-Salhy M., Wendelbo I., Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease, Mol. Med. Rep. 2013; 8: 451–455.Faure C., Patey N., Gauthier C., Brooks E. M., Mawe G. M. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients, Gastroenterology. 2010; 139: 249–258. DOI: 10.1053/j.gastro.2010.03.032Faure C., Patey N., Gauthier C., Brooks E. M., Mawe G. M. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients, Gastroenterology. 2010; 139: 249–258. DOI: 10.1053/j.gastro.2010.03.032Zhang L. Y., Dong X., Liu Z. L., Mo J. Z., Fang J. Y., Xiao S. D. et al. Luminal serotonin time-dependently modulates vagal afferent driven antinociception in response to colorectal distention in rats, Neurogastroenterol. Motil. 2011; 3: 62–69. DOI: 10.1111/j.1365-2982.2010.01589Zhang L. Y., Dong X., Liu Z. L., Mo J. Z., Fang J. Y., Xiao S. D. et al. Luminal serotonin time-dependently modulates vagal afferent driven antinociception in response to colorectal distention in rats, Neurogastroenterol. Motil. 2011; 3: 62–69. DOI: 10.1111/j.1365-2982.2010.01589Li C. P., Ling C., Biancani P., Behar J. Effect of progesterone on colonic motility and fecal output in mice with diarrhea, Neurogastroenterol. Motil. 2012; 24: 392–e174Li C. P., Ling C., Biancani P., Behar J. Effect of progesterone on colonic motility and fecal output in mice with diarrhea, Neurogastroenterol. Motil. 2012; 24: 392–e174Greig J., Gandotra N., Tackett J. J., Bamdad M. C., Cowles R. A. Enhanced serotonin signaling increases intestinal neuroplasticity, J. Surg. Res. 2016; 206: 151–158. DOI: 10.14814/phy2.14278Greig J., Gandotra N., Tackett J. J., Bamdad M. C., Cowles R. A. Enhanced serotonin signaling increases intestinal neuroplasticity, J. Surg. Res. 2016; 206: 151–158. DOI: 10.14814/phy2.14278Bischoff S. C., Mailer R., Pabst O., Weier G., Sedlik W., Li Z. et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice, Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G685–G695. DOI:10.3390/ijms22179487Bischoff S. C., Mailer R., Pabst O., Weier G., Sedlik W., Li Z. et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice, Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G685–G695. DOI:10.3390/ijms22179487Yu F. Y., Huang S. G., Zhang H. Y., Ye H., Chi H. G., Zou Y. et al. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis, World J. Gastroenterol. 2016; 22: 3451–3459. DOI:10.3748/wjg.v20.i41.15299Yu F. Y., Huang S. G., Zhang H. Y., Ye H., Chi H. G., Zou Y. et al. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis, World J. Gastroenterol. 2016; 22: 3451–3459. DOI:10.3748/wjg.v20.i41.15299Zou B. C., Dong L., Wang Y., Wang S. H., Cao M. B. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome, Chin. Med. J. 2007; 120: 2069–2074.Zou B. C., Dong L., Wang Y., Wang S. H., Cao M. B. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome, Chin. Med. J. 2007; 120: 2069–2074.Lembo A., Sultan S., Chang L., Heidelbaugh J. J., Smalley W., Verne G. N. AGA clinical practice guideline on the pharmacological Management of Irritable Bowel Syndrome with Diarrhea, Gastroenterology. 2022; 163: 137–151.Lembo A., Sultan S., Chang L., Heidelbaugh J. J., Smalley W., Verne G. N. AGA clinical practice guideline on the pharmacological Management of Irritable Bowel Syndrome with Diarrhea, Gastroenterology. 2022; 163: 137–151.Camilleri M., Boeckxstaens G. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Gut. 2023; 72: 590–599. DOI: 10.1136/gutjnl-2022-328515Camilleri M., Boeckxstaens G. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Gut. 2023; 72: 590–599. DOI: 10.1136/gutjnl-2022-328515Kim J. J., Bridle B. W., Ghia J. E., Wang H., Syed S. N., Manocha M. M. et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation, J. Immunol. 2013; 190: 4795–4804.Kim J. J., Bridle B. W., Ghia J. E., Wang H., Syed S. N., Manocha M. M. et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation, J. Immunol. 2013; 190: 4795–4804.Yaakob N. S., Chinkwo K. A., Chetty N., Coupar I. M., Irving H. R. Distribution of 5HT3, 5-HT4, and 5-HT7 receptors along the human Colon, J Neurogastroenterol Motil. 2015; 21: 361–369. DOI:10.5056/jnm15093Yaakob N. S., Chinkwo K. A., Chetty N., Coupar I. M., Irving H. R. Distribution of 5HT3, 5-HT4, and 5-HT7 receptors along the human Colon, J Neurogastroenterol Motil. 2015; 21: 361–369. DOI:10.5056/jnm15093Гаус О. В., Ливзан М. А. Модуляция микробиоты кишечника как ведущий фактор патогенеза формирования фенотипов СРК. РМЖ. 2023; 5: 20–26.Gaus O. V., Livzan M. A. Modulation of intestinal microbiota as a leading factor in the pathogenesis of the formation of IBS phenotypes. RMJ. 2023; 5: 20–26. (In Russ.).El-Salhy M., Hatlebakk J. G., Gilja O. H., Brathen Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020; 69: 859–867.El-Salhy M., Hatlebakk J. G., Gilja O. H., Brathen Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020; 69: 859–867.Su Q., Tun H. M., Liu Q., Yeoh Y. K., Mak J. W.Y., Chan F. K. et al. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome, Gut Microbes 15 (2023), 2157697Su Q., Tun H. M., Liu Q., Yeoh Y. K., Mak J. W.Y., Chan F. K. et al. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome, Gut Microbes 15 (2023), 2157697Dicksved J., Ellström P., Engstrand L., Rautelin H. Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota. mBio. 2014; 5(5): e01212–14.Dicksved J., Ellström P., Engstrand L., Rautelin H. Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota. mBio. 2014; 5(5): e01212–14.Jalanka-Tuovinen J., Salojärvi J., Salonen A. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014; 63(11): 1737–1745Jalanka-Tuovinen J., Salojärvi J., Salonen A. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014; 63(11): 1737–1745Zuo T. Zhang F., Lui G. C.Y., Yeoh Y. K., Li A. Y.L., Zhan H. et al. Alterations in Gut Microbiota of Patients With COVID 19 During Time of Hospitalization. Gastroenterology. 2020; 159 (3): 944–955.e8. DOI:10.1053/j.gastro.2020.05.048 33.Zuo T. Zhang F., Lui G. C.Y., Yeoh Y. K., Li A. Y.L., Zhan H. et al. Alterations in Gut Microbiota of Patients With COVID 19 During Time of Hospitalization. Gastroenterology. 2020; 159 (3): 944–955.e8. DOI:10.1053/j.gastro.2020.05.048 33.Barandouzi Z. A., Lee J., Del Carmen Rosas M., Chen J., Henderson W. A., Starkweather A. R. et al. Associations of neurotransmitters and the gut microbiome with emotional distress in mixed type of irritable bowel syndrome. Sci Rep. 2022; 12(1): 1648 DOI: 10.1038/s41598-022-05756-0].Barandouzi Z. A., Lee J., Del Carmen Rosas M., Chen J., Henderson W. A., Starkweather A. R. et al. Associations of neurotransmitters and the gut microbiome with emotional distress in mixed type of irritable bowel syndrome. Sci Rep. 2022; 12(1): 1648 DOI: 10.1038/s41598-022-05756-0].Lyte M. Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog. 2013; 9(11): e1003726. DOI: 10.1371/journal.ppat.1003726Lyte M. Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog. 2013; 9(11): e1003726. DOI: 10.1371/journal.ppat.1003726Yano J. M., Yu K., Donaldson G. P., Shastri G. G., Ann P., Ma L. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161: 264–276.Yano J. M., Yu K., Donaldson G. P., Shastri G. G., Ann P., Ma L. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161: 264–276.Yang J., Wang P., Liu T., Lin L., Li L., Kou G. et al. Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome. BMC Microbiol. 2021; 21(1): 316. DOI: 10.1186/s12866-021-02380-2.].Yang J., Wang P., Liu T., Lin L., Li L., Kou G. et al. Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome. BMC Microbiol. 2021; 21(1): 316. DOI: 10.1186/s12866-021-02380-2.].Sun Q., Jia Q., Song L., Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(7): e14513. DOI: 10.1097/MD.0000000000014513Sun Q., Jia Q., Song L., Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(7): e14513. DOI: 10.1097/MD.0000000000014513Shaidullov I. F., Sorokina D. M., Sitdikov F. G., Hermann A., Abdulkhakov S. R., Sitdikova G. F. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome. BMC Gastroenterol. 2021; 21(1): 37. DOI: 10.1186/s12876-021-01613-y.Shaidullov I. F., Sorokina D. M., Sitdikov F. G., Hermann A., Abdulkhakov S. R., Sitdikova G. F. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome. BMC Gastroenterol. 2021; 21(1): 37. DOI: 10.1186/s12876-021-01613-y.Peleman C., Camilleri M., Busciglio I., Burton D., Donato L., Zinsmeister A. R. Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption. Clin Gastroenterol Hepatol. 2017; 15(5): 720–727.e1. DOI: 10.1016/j.cgh.2016.11.012.Peleman C., Camilleri M., Busciglio I., Burton D., Donato L., Zinsmeister A. R. Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption. Clin Gastroenterol Hepatol. 2017; 15(5): 720–727.e1. DOI: 10.1016/j.cgh.2016.11.012.Camilleri M., Carlson P., Acosta A., Busciglio I. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. Am J Physiol Gastrointest Liver Physiol. 2015; 309(1): G10–20. DOI: 10.1152/ajpgi.00080.2015.Camilleri M., Carlson P., Acosta A., Busciglio I. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. Am J Physiol Gastrointest Liver Physiol. 2015; 309(1): G10–20. DOI: 10.1152/ajpgi.00080.2015.Zhao L., Yang W., Chen Y., Huang F., Lu L., Lin C. et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020; 130(1): 438–450. DOI: 10.1172/JCI130976.Zhao L., Yang W., Chen Y., Huang F., Lu L., Lin C. et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020; 130(1): 438–450. DOI: 10.1172/JCI130976.Zhan K., Wu H., Xu Y., Rao K., Zheng H., Qin S. et al. The function of the gut microbiota-bile acid-TGR 5 axis in diarrhea-predominant irritable bowel syndrome. mSystems. 2024; 9(3): e0129923. DOI: 10.1128/msystems.01299-23.Zhan K., Wu H., Xu Y., Rao K., Zheng H., Qin S. et al. The function of the gut microbiota-bile acid-TGR 5 axis in diarrhea-predominant irritable bowel syndrome. mSystems. 2024; 9(3): e0129923. DOI: 10.1128/msystems.01299-23.Chong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136.Chong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136.Simon E., Călinoiu L. F., Mitrea L., Vodnar D. C. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 2021; 13(6): 2112. DOI: 10.3390/nu13062112Simon E., Călinoiu L. F., Mitrea L., Vodnar D. C. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 2021; 13(6): 2112. DOI: 10.3390/nu13062112Ford A. C., Moayyedi P., Lacy B. E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. 2014; 109: S 2–S 27. DOI: 10.1038/ajg.2014.187Ford A. C., Moayyedi P., Lacy B. E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. 2014; 109: S 2–S 27. DOI: 10.1038/ajg.2014.187Su G. L., Ko C. W., Bercik P. et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020; 159 (2): 697–705. DOI: 10.1053/j.gastro.2020.05.059Su G. L., Ko C. W., Bercik P. et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020; 159 (2): 697–705. DOI: 10.1053/j.gastro.2020.05.059World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. [electronic resource] – Available from: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-englishWorld Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. [electronic resource] – Available from: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-englishИвашкин В. Т., Горелов А. В., Абдулганиева Д. И., Алексеева О. П., Алексеенко С. А., Барановский А.Ю. и др. Методические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков, метабиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у взрослых и детей. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024. DOI:10.22416/1382-4376-2024-117-312Ivashkin V. T., Gorelov A. V., Abdulganieva D. I., Alekseeva O. P., Alekseenko S. A., Baranovsky A. Yu. et al. Methodical recommendations of the Scientific Society for the Promotion of Clinical Study of the Human Microbiome (NSCMSHM) and the Russian Gastroenterological Association (RGA) on the use of probiotics, prebiotics, synbiotics, metabiotics and functional food products enriched with them for the treatment and prevention of gastrointestinal diseases in adults and children. Russian Journal of Gastroenterology, Hepatology, Proctology. 2024. (In Russ.). DOI: 10.22416/1382-4376-2024-117-312Vasant D. H., Paine P. A., Black C. J. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214–1240. DOI: 10.1136/gutjnl-2021-324598Vasant D. H., Paine P. A., Black C. J. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214–1240. DOI: 10.1136/gutjnl-2021-324598Tiwari S. K., Dicks L. M.T., Popov I. V., Karaseva A., Ermakov A. M., Suvorov A. et al. Probiotics at War Against Viruses: What Is Missing From the Picture? Front. Microbiol. 2020; 11: 1877. DOI: 10.3389/fmicb.2020.01877Tiwari S. K., Dicks L. M.T., Popov I. V., Karaseva A., Ermakov A. M., Suvorov A. et al. Probiotics at War Against Viruses: What Is Missing From the Picture? Front. Microbiol. 2020; 11: 1877. DOI: 10.3389/fmicb.2020.01877Chiba Y., Shida K., Nagata S., Wada M., Bian L., Wang C. et al. Well-Controlled Proinflammatory Cytokine Responses of Peyer’s Patch Cells to Probiotic Lactobacillus Casei. Immunology. 2010; 130: 352–362. DOI: 10.1111/j.1365-2567.2009.03204.xChiba Y., Shida K., Nagata S., Wada M., Bian L., Wang C. et al. Well-Controlled Proinflammatory Cytokine Responses of Peyer’s Patch Cells to Probiotic Lactobacillus Casei. Immunology. 2010; 130: 352–362. DOI: 10.1111/j.1365-2567.2009.03204.xChowdhury A. H., Cámara M., Verma C., Eremin O., Kulkarni A. D., Lobo D. N. Modulation of T Regulatory and Dendritic Cell Phenotypes Following Ingestion of Bifidobacterium Longum, AHCC® and Azithromycin in Healthy Individuals. Nutrients. 2019; 11: 2470. DOI: 10.3390/nu11102470.Chowdhury A. H., Cámara M., Verma C., Eremin O., Kulkarni A. D., Lobo D. N. Modulation of T Regulatory and Dendritic Cell Phenotypes Following Ingestion of Bifidobacterium Longum, AHCC® and Azithromycin in Healthy Individuals. Nutrients. 2019; 11: 2470. DOI: 10.3390/nu11102470.Trabattoni D., Parisotto S., Borgonovo L., Toscano M., Rizzardini G., Clerici M. et al. Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis. J. Clin. Gastroenterol. 2012; 46: S 33–S 40. DOI: 10.1097/MCG.0b013e31826a8468.Trabattoni D., Parisotto S., Borgonovo L., Toscano M., Rizzardini G., Clerici M. et al. Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis. J. Clin. Gastroenterol. 2012; 46: S 33–S 40. DOI: 10.1097/MCG.0b013e31826a8468.Dwivedi M., Kumar P., Laddha N. C., Kemp E. H. Induction of Regulatory T Cells: A Role for Probiotics and Prebiotics to Suppress Autoimmunity. Autoimmun. Rev. 2016; 15:3 79–392. DOI: 10.1016/j.autrev.2016.01.002Dwivedi M., Kumar P., Laddha N. C., Kemp E. H. Induction of Regulatory T Cells: A Role for Probiotics and Prebiotics to Suppress Autoimmunity. Autoimmun. Rev. 2016; 15:3 79–392. DOI: 10.1016/j.autrev.2016.01.002Wu Y., Li Y., Zheng Q., Li L. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2024; 16(13): 2114. DOI: 10.3390/nu16132114.Wu Y., Li Y., Zheng Q., Li L. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2024; 16(13): 2114. DOI: 10.3390/nu16132114.O'Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128(3): 541–551. DOI: 10.1053/j.gastro.2004.11.050O'Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128(3): 541–551. DOI: 10.1053/j.gastro.2004.11.050Zakostelska Z., Kverka M., Klimesova K. et al. Lysate of probiotic Lactobacillus casei DN-114001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011; 6(11): e27961. DOI: 10.1371/journal.pone.0027961.Zakostelska Z., Kverka M., Klimesova K. et al. Lysate of probiotic Lactobacillus casei DN-114001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011; 6(11): e27961. DOI: 10.1371/journal.pone.0027961.Ferrario C., Taverniti V., Milani C. et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014; 144(11): 1787–1796. DOI: 10.3945/jn.114.197723.Ferrario C., Taverniti V., Milani C. et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014; 144(11): 1787–1796. DOI: 10.3945/jn.114.197723.D'Incà R., Barollo M., Scarpa M. et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011; 56(4): 1178–1187. DOI: 10.1007/s10620-010-1384-1.D'Incà R., Barollo M., Scarpa M. et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011; 56(4): 1178–1187. DOI: 10.1007/s10620-010-1384-1.Cremon C., Guglielmetti S., Gargari G. et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United. European. Gastroenterol. J. 2018; 6(4): 604–613. DOI: 10.1177/2050640617736478Cremon C., Guglielmetti S., Gargari G. et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United. European. Gastroenterol. J. 2018; 6(4): 604–613. DOI: 10.1177/2050640617736478Connell M., Shin A., James-Stevenson T. et al. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterology and motility. 2018; 30(12): e13427. DOI:10.1111/nmo.13490Connell M., Shin A., James-Stevenson T. et al. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterology and motility. 2018; 30(12): e13427. DOI:10.1111/nmo.13490

The authors declare that there are no conflicts of interest present.